60 Degrees Pharmaceuticals Llc

This phase 2 study tests the drug tafenoquine in 40 adults with chronic babesiosis who have severe fatigue. The goal is to see if tafenoquine can reduce fatigue and clear the Babesia parasite from the blood. Participants take the drug and report their fatigue levels using a stand…

This expanded access program offers tafenoquine to immunocompromised adults with persistent babesiosis who have not improved with standard treatments. Patients take the drug daily for 4 days, then weekly until two negative tests confirm the infection is gone. The goal is to clear…

This study tests whether adding an oral drug called tafenoquine to standard antibiotics helps hospitalized adults with babesiosis recover faster. Babesiosis is a tick-borne illness that can cause fever, chills, and fatigue. About 33 participants will receive either tafenoquine or…